/FBLG
FBLG Stock - FibroBiologics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$0.26-0.92%
$0.00 (-0.92%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+3381.6%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FBLG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.26 – $0.26
TARGET (TP)$9.00
STOP LOSS$0.24
RISK/REWARD1:472.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.57
52W High$2.51
52W Low$0.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-13,737,000 | $-8,889,000 | $-4,467,000 | $-1,578,000 | $-1,169,000 |
| Net Income | $-11,161,000 | $-16,485,000 | $-5,121,000 | $-1,582,000 | $-1,169,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.34 | $-0.59 | $-0.16 | $-0.05 | $-0.04 |
Company Overview
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 4542.2% Upside
Now
$12
Low
$12
Average
$12
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2024 | Rodman & Renshaw | Initiation | Buy | $12 |
| October 30th 2024 | H.C. Wainwright | Initiation | Buy | $12 |
| September 24th 2024 | Maxim Group | Initiation | Buy | $12 |
Earnings History & Surprises
FBLGBeat Rate
33%
Last 6 quarters
Avg Surprise
-3.9%
EPS vs Estimate
Beats / Misses
2/2
2 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
0.0%
$-0.09vs$-0.09
Q4 24
0.0%
$-0.08vs$-0.08
Q1 25
+5.7%
$-0.09vs$-0.10
Q1 25
+10.0%
$-0.09vs$-0.10
Q3 25
-9.1%
$-0.12vs$-0.11
Q4 25
-30.0%
$-0.13vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.09 | — | — | — |
Q4 2025 | Oct 31, 2025 | $-0.10 | $-0.13 | -30.0% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.10 | $-0.09 | +5.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.08 | $-0.08 | 0.0% | = MET |
Q3 2024 | Aug 7, 2024 | $-0.09 | $-0.09 | 0.0% | = MET |
Q2 2024 | May 14, 2024 | — | $-0.27 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.34 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.07 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.07 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.07 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.05 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.05 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.04 | — | — |
Latest News
FibroBiologics shares are trading lower after the company announced a $1.7 million registered direct offering of 5.2 million shares at a price of $0.33 per share.
📉 NegativeBenzinga•Dec 15, 2025, 05:06 PM
FibroBiologics Announces $1.7M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules; 5,227,275 Shares At $0.33/Share
➖ NeutralBenzinga•Dec 15, 2025, 01:01 PM
FibroBiologics Files New USPTO Patent For Fibroblast-Derived Spheroid Platform Aimed At Cartilage And Disc Repair
📈 PositiveBenzinga•Dec 10, 2025, 01:35 PM
FibroBiologics Announces That It Has Fully Repaid All Outstanding Amounts Under Its Convertible Promissory Notes Issued To Yorkville
📈 PositiveBenzinga•Nov 26, 2025, 01:35 PM
FibroBiologics shares are trading lower after the company announced a $1.5 million registered direct offering of 4.48 million shares at $0.335 per share.
📉 NegativeBenzinga•Nov 24, 2025, 02:14 PM
FibroBiologics Enters Agreements To Raise Capital Through A $1.5M Registered Direct Offering Of 4.48M Common Shares At $0.335 Per Share
➖ NeutralBenzinga•Nov 24, 2025, 02:04 PM
D. Boral Capital Maintains Buy on FibroBiologics, Maintains $15 Price Target
📈 PositiveBenzinga•Nov 20, 2025, 01:08 PM
FibroBiologics Receives HREC Approval In Australia For Phase 1/2 Clinical Trial for CYWC628 For Refractory Diabetic Foot Ulcers
📈 PositiveBenzinga•Nov 20, 2025, 01:06 PM
FBLG stock has given up its prior loss. FibroBiologics shares were trading lower after the company priced a $4 million registered direct offering.
➖ NeutralBenzinga•Nov 19, 2025, 06:21 PM
FibroBiologics Announces $4M Registered Direct Offering Of 3.54M Shares And Pre Funded Warrants To Purchase 8.57M Shares, At A Price Of $0.3303 Each In Gold-Backed Offering
➖ NeutralBenzinga•Nov 19, 2025, 01:42 PM•Also: , ,
FibroBiologics shares are trading lower after the company priced a $4 million registered direct offering.
📉 NegativeBenzinga•Nov 19, 2025, 01:38 PM
HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 5, 2025, 11:29 AM
Watching FibroBiologics; Zacks Small-Cap Research Gives Stock $11.00 Price Valuation
📈 PositiveBenzinga•Nov 4, 2025, 07:06 PM
FibroBiologics Prepares To Submit IND Applications For Treatment Of Psoriasis With CYPS317 And Treatment Of Multiple Sclerosis With CYMS101
📈 PositiveBenzinga•Oct 31, 2025, 08:33 PM
FibroBiologics, Inc. - Common Stock Q3 EPS $(0.13) Misses $(0.11) Estimate
📉 NegativeBenzinga•Oct 31, 2025, 08:31 PM
HC Wainwright & Co. Reiterates Buy on FibroBiologics, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 12, 2025, 10:28 AM
FibroBiologics Announces IND-Enabling Updates From Psoriasis Research Program Demonstrating Potential Of Human Dermal Fibroblast Spheroids As Novel Therapeutic Approach For Chronic-Relapse Psoriasis.
📈 PositiveBenzinga•Sep 11, 2025, 12:36 PM
D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target
📈 PositiveBenzinga•Sep 10, 2025, 03:18 PM
FibroBiologics Advances Bone Marrow Organoid Platform Offering New Treatment Options For Hematopoietic Cancers And Age-Related Immune Decline
📈 PositiveBenzinga•Sep 10, 2025, 12:35 PM
Frequently Asked Questions about FBLG
What is FBLG's current stock price?
FibroBiologics, Inc. Common Stock (FBLG) is currently trading at $0.26 per share. The stock has moved -0.92% today.
What is the analyst price target for FBLG?
The average analyst price target for FBLG is $9.00, based on 1 analyst.
What sector is FibroBiologics, Inc. Common Stock in?
FibroBiologics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FBLG's market cap?
FibroBiologics, Inc. Common Stock has a market capitalization of $0.01 billion, making it a small-cap company.
Does FBLG pay dividends?
No, FibroBiologics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
AIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
HOTH
Hoth Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
Explore stocks similar to FBLG for comparison